New study aims to help thousands better manage type 2 diabetes

NCT ID NCT06251323

First seen Nov 01, 2025 · Last updated Jun 19, 2026 · Updated 34 times

Summary

This large study tests a new way of delivering diabetes care called iPATH, which uses a team of providers and technology to help patients better control their blood sugar. Researchers will enroll about 120,000 adults with type 2 diabetes at 16 community health centers across the U.S. The goal is to see if this approach can reduce the number of patients with dangerously high blood sugar levels.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DIABETES MELLITUS, TYPE 2 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Board of Trustees of the Leland Stanford Junior University

    RECRUITING

    Stanford, California, 94305, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • Impactivo, LLC.

    RECRUITING

    San Juan, Puerto Rico, 00907, Puerto Rico

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • President and Fellows of Harvard College, T.H. Chan School

    RECRUITING

    Boston, Massachusetts, 02115, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Ohio State University

    RECRUITING

    Columbus, Ohio, 43210, United States

    Contact Phone: •••-•••-•••• Email: •••••@•••••

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

iPATH implementation approach (team-based, technology-enabled care model)

What this could lead to

If successful, this could provide a scalable way to improve diabetes management in underserved communities, reducing complications from poorly controlled blood sugar.

What could go wrong

This is an implementation study, not a drug trial, so benefits depend on how well clinics adopt the new approach. Results may vary across different health centers and patient populations.

Conditions

The condition(s) this trial relates to.

type 2 diabetes mellitus

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.